AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29969928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium as add-on therapy to inhaled corticosteroids
Number of subjects: 536
Study 29969928 — intervention group
Group type: COMPARATOR
Intervention: Long acting beta agonist as add-on therapy to inhaled corticosteroids
Number of subjects: 536
Study 28935773 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/nab-paclitaxel plus apatorsen
Number of subjects: 132
Study 28935773 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/nab-paclitaxel plus placebo
Number of subjects: 132
Study 28935773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 132
Study 27473445 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity low-volume training (HIT)
Number of subjects: 62
Study 27473445 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 62
Study 25275069 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily erlotinib for 12 consecutive days prior to docetaxel (Arm A)
Number of subjects: 50
Study 25275069 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by daily erlotinib (Arm B)
Number of subjects: 50
Study 22934861 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education
Number of subjects: 100
Study 22934861 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 19605762 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training for 3 months
Number of subjects: 17
Study 19605762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no endurance training)
Number of subjects: 17
Study 17488457 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose clamped at 5 mmol/l
Number of subjects: 9
Study 17488457 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose clamped at 15 mmol/l
Number of subjects: 9
Study 15337134 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500 mg b.d., titrated to a maximum of 3 g/day
Number of subjects: 10
Study 15337134 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) for patients with Lennox-Gastaut syndrome (LGS)
Number of subjects: 10
Study 16894771 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and 1H MR spectroscopy
Number of subjects: 0
Study 10463847 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoclonic Astatic Epilepsy (MAE) - Group 1 (37 children)
Number of subjects: 72
Study 10463847 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoclonic Astatic Epilepsy (MAE) - Group 2 (18 children)
Number of subjects: 72
Study 10463847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lennox-Gastaut Syndrome - Group 3 (11 children)
Number of subjects: 72
Study 8903618 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors monotherapy
Number of subjects: 125
Study 11527126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg o.d.
Number of subjects: 41
Study 11527126 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 50 mg o.d.
Number of subjects: 41
Study 358381 — intervention group
Group type: EXPERIMENTAL
Intervention: Norephedrine
Number of subjects: 25
Study 358381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31747385 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 289
Study 31747385 — intervention group
Group type: COMPARATOR
Intervention: Written information sheet (Control)
Number of subjects: 289
Study 30773862 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep acupuncture of CV22 + rehabilitation training
Number of subjects: 70
Study 30773862 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture + swallowing rehabilitation training
Number of subjects: 70
Study 28067701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic preconditioning with sevoflurane
Number of subjects: 129
Study 28067701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic postconditioning with sevoflurane
Number of subjects: 129
Study 28067701 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (control)
Number of subjects: 129
Study 25968121 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-part alcohol brief intervention (BI)
Number of subjects: 0
Study 25968121 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 0
Study 25968121 — intervention group
Group type: COMPARATOR
Intervention: Attention control with limited assessment (AC)
Number of subjects: 0
Study 23407853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin monotherapy (100 mg)
Number of subjects: 29
Study 23407853 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (40 mg for 5 days) + Sitagliptin (100 mg on day 5)
Number of subjects: 29
Study 19939876 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine/phenylalanine depletion (TPD)
Number of subjects: 17
Study 19939876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 17
Study 19732668 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAX‐2000
Number of subjects: 65
Study 19732668 — intervention group
Group type: EXPERIMENTAL
Intervention: Haas
Number of subjects: 65
Study 19732668 — intervention group
Group type: EXPERIMENTAL
Intervention: MAX‐2000
Number of subjects: 65
Study 19732668 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study 17762445 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrum Silver (multivitamins)
Number of subjects: 40
Study 17762445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15565033 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mL vacuum collection tubes
Number of subjects: 12
Study 15565033 — intervention group
Group type: COMPARATOR
Intervention: 10-mL vacuum collection tubes
Number of subjects: 12
Study 11487548 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d for 1 week
Number of subjects: 36
Study 11487548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9851896 — intervention group
Group type: EXPERIMENTAL
Intervention: C282Y mutation homozygosity in patients with grade 3 or 4 hepatic iron deposition
Number of subjects: 78
Study 9851896 — intervention group
Group type: EXPERIMENTAL
Intervention: C282Y mutation homozygosity in patients with <3+ iron deposition
Number of subjects: 78
Study 9851896 — intervention group
Group type: EXPERIMENTAL
Intervention: C282Y and H63D mutation heterozygosity
Number of subjects: 78
Study 9851896 — intervention group
Group type: COMPARATOR
Intervention: C282Y mutation heterozygosity in control individuals
Number of subjects: 78
Study 9851896 — intervention group
Group type: COMPARATOR
Intervention: H63D mutation heterozygosity in control individuals
Number of subjects: 78
Study 9130897 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 49
Study 1928474 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 80 mg/day)
Number of subjects: 21
Study 1928474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7036799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 per cent bupivacaine HCl
Number of subjects: 60
Study 7036799 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 per cent lidocaine HCl
Number of subjects: 60
Study 7036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-bupivacaine mixture (1:3)
Number of subjects: 60
Study 7036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-bupivacaine mixture (1:1)
Number of subjects: 60
Study 7036799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-bupivacaine mixture (3:1)
Number of subjects: 60
Study 30915491 — intervention group
Group type: COMPARATOR
Intervention: 5 cycles of sham conditioning
Number of subjects: 40
Study 30915491 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of RLIC
Number of subjects: 40
Study 30915491 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of RLIC
Number of subjects: 40
Study 30915491 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cycles of RLIC
Number of subjects: 40
Study 29129252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 360
Study 29129252 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 360
Study 26645407 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) trastuzumab 600 mg
Number of subjects: 595
Study 26645407 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) trastuzumab (weight-based)
Number of subjects: 595
Study 25551934 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 80
Study 22750044 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message immunization reminders prior to immunization due dates
Number of subjects: 90
Study 22750044 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 90
Study 20465344 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-sensitive prevention programs
Number of subjects: 19
Study 20465344 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcultural perspectives on suicidal behaviors
Number of subjects: 19
Study 19134350 — intervention group
Group type: EXPERIMENTAL
Intervention: Group G (puberty gingivitis)
Number of subjects: 54
Study 19134350 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (chronic periodontitis)
Number of subjects: 54
Study 19134350 — intervention group
Group type: COMPARATOR
Intervention: Group H (healthy controls)
Number of subjects: 54
Study 19134350 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-moderate group
Number of subjects: 54
Study 19134350 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe inflammation group
Number of subjects: 54
Study 19134350 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe gingivitis group
Number of subjects: 54
Study 19134350 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 54
Study 15865498 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 50
Study 15865498 — intervention group
Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 50
Study 12876091 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg three times a day
Number of subjects: 1368
Study 12876091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1368
Study 10554851 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for thoracic aortic aneurysm in patients aged 70 years or older
Number of subjects: 261
Study 9097988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (750 mg four times a day for 48 weeks)
Number of subjects: 293
Study 9097988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 9097988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine
Number of subjects: 293
Study 1288906 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 34
Study 1288906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 1288906 — intervention group
Group type: COMPARATOR
Intervention: EMLA/Placebo
Number of subjects: 34
Study 3010696 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 139
Study 3010696 — intervention group
Group type: COMPARATOR
Intervention: Compazine
Number of subjects: 139
Study 3010696 — intervention group
Group type: EXPERIMENTAL
Intervention: THC and Compazine
Number of subjects: 139
Study 30882555 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 0
Study 30882555 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 0
Study 30415664 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlocked Group (UG)
Number of subjects: 240
Study 30415664 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Group (DG)
Number of subjects: 240
Study 30415664 — intervention group
Group type: COMPARATOR
Intervention: Static Group (SG)
Number of subjects: 240
Study 30415664 — intervention group
Group type: EXPERIMENTAL
Intervention: All Groups
Number of subjects: 240
Study 27998900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice
Number of subjects: 246
Study 27998900 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-deplete beetroot juice (placebo)
Number of subjects: 246
Study 25263513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal cooling
Number of subjects: 108
Study 25263513 — intervention group
Group type: COMPARATOR
Intervention: Standard care without pharyngeal cooling
Number of subjects: 108
Study 22284965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis GCL2505
Number of subjects: 17
Study 22284965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18814805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycaemic index (GI)
Number of subjects: 29133
Study 18814805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary glycaemic load (GL)
Number of subjects: 29133
Study 18814805 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing GI
Number of subjects: 29133
Study 18814805 — intervention group
Group type: EXPERIMENTAL
Intervention: GL
Number of subjects: 29133
Study 17907289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin, 5-FU, and enteric-coated tegafur/uracil
Number of subjects: 10
Study 17907289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy
Number of subjects: 10
Study 15167313 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (while continuing 2.5 mg of oral medroxyprogesterone acetate)
Number of subjects: 61
Study 15167313 — intervention group
Group type: COMPARATOR
Intervention: Oral estrogen (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 61
Study 11181465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d for 3 months
Number of subjects: 24
Study 8485792 — intervention group
Group type: EXPERIMENTAL
Intervention: Orogastric tube aspiration
Number of subjects: 265
Study 8485792 — intervention group
Group type: COMPARATOR
Intervention: Control (no tube inserted)
Number of subjects: 265
Study 3326743 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Lf diphtheria vaccine
Number of subjects: 200
Study 3326743 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 Lf diphtheria vaccine
Number of subjects: 200
Study 3326743 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 29268022 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection into the rotator interval (RI)
Number of subjects: 77
Study 29268022 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection into the intra-articular (IA) space
Number of subjects: 77
Study 29268022 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection into the subacromial (SA) space
Number of subjects: 77
Study 28577840 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCHMAN implant
Number of subjects: 1025
Study 24391022 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD sequence (free-breathing)
Number of subjects: 23
Study 24391022 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI treatment
Number of subjects: 23
Study 24391022 — intervention group
Group type: COMPARATOR
Intervention: Standard breath-hold gradient echo sequence
Number of subjects: 23
Study 23216382 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day)
Number of subjects: 23
Study 22010585 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 82
Study 22010585 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 82
Study 18309140 — intervention group
Group type: EXPERIMENTAL
Intervention: US-born Black women
Number of subjects: 0
Study 18309140 — intervention group
Group type: COMPARATOR
Intervention: Black West Indian men
Number of subjects: 0
Study 18309140 — intervention group
Group type: COMPARATOR
Intervention: Black West Indian women
Number of subjects: 0
Study 16448518 — intervention group
Group type: EXPERIMENTAL
Intervention: Packaged portion‐controlled entrees (Group E, n = 25)
Number of subjects: 60
Study 16448518 — intervention group
Group type: COMPARATOR
Intervention: Self‐selected diet (Group P, n = 26)
Number of subjects: 60
Study 12624861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiredness Management Guide (TMG)
Number of subjects: 68
Study 12624861 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 11099709 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 251
Study 11099709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 9496207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-incisional extradural analgesia
Number of subjects: 20
Study 9496207 — intervention group
Group type: COMPARATOR
Intervention: No pre-incisional extradural analgesia (Control)
Number of subjects: 20
Study 9496207 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-extradural analgesia during operation
Number of subjects: 20
Study 9496207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during emergence from anaesthesia
Number of subjects: 20
Study 8211679 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal splenorenal shunt (PSRS)
Number of subjects: 48
Study 8211679 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 48
Study 3669757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid alpha-interferon (3 mega units daily subcutaneously until complete or partial response)
Number of subjects: 82
Study 3669757 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance regime of 3 mega units/week
Number of subjects: 82
Study 3669757 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 82
Study 3669757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid alpha-interferon
Number of subjects: 82
Study 31781921 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirrored images of the left femur using the right as a template
Number of subjects: 10
Study 31781921 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Trauma and CT motion analysis (CTMA)
Number of subjects: 10
Study 29565302 — intervention group
Group type: EXPERIMENTAL
Intervention: UNICEF Laos WinS project
Number of subjects: 0
Study 29565302 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily group hygiene activities
Number of subjects: 0
Study 29565302 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary strategy for individual handwashing practice
Number of subjects: 0
Study 27837658 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ/ZIP (switch from olanzapine to ziprasidone after 4 weeks)
Number of subjects: 148
Study 27837658 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ + ZIP (combination therapy)
Number of subjects: 148
Study 27837658 — intervention group
Group type: COMPARATOR
Intervention: ZIP (ziprasidone monotherapy)
Number of subjects: 148
Study 27837658 — intervention group
Group type: COMPARATOR
Intervention: OLZ (olanzapine monotherapy)
Number of subjects: 148
Study 25424689 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg plus lercanidipine 5 mg (Group A)
Number of subjects: 180
Study 25424689 — intervention group
Group type: COMPARATOR
Intervention: Lercanidipine 10 mg (Group B)
Number of subjects: 180
Study 25424689 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 4 mg (Group C)
Number of subjects: 180
Study 24034661 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg/d
Number of subjects: 1978
Study 21883574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological approach intervention including a two-hour seminar and a brochure about health and development during puberty
Number of subjects: 228
Study 21883574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 228
Study 19398081 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (n = 27)
Number of subjects: 54
Study 19398081 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 27)
Number of subjects: 54
Study 17957418 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote simultaneous medical interpreting (RSMI)
Number of subjects: 22
Study 17957418 — intervention group
Group type: COMPARATOR
Intervention: Proximate ad hoc interpreting
Number of subjects: 22
Study 17957418 — intervention group
Group type: COMPARATOR
Intervention: Non-RSMI encounters
Number of subjects: 22
Study 15050265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nagahara phaco‐chop technique (Group 1)
Number of subjects: 70
Study 15050265 — intervention group
Group type: COMPARATOR
Intervention: Stop-and-chop technique (Group 2)
Number of subjects: 70
Study 11348939 — intervention group
Group type: EXPERIMENTAL
Intervention: SR bupropion treatment (100, 150, or 300 mg/d) for 7 weeks
Number of subjects: 615
Study 11348939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 8989016 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms/kg and neostigmine 50 micrograms/kg (Group A)
Number of subjects: 30
Study 8989016 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 8 micrograms/kg and neostigmine 50 micrograms/kg (Group G)
Number of subjects: 30
Study 8989016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 30
Study 8484510 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.8% and 1.2%)
Number of subjects: 13
Study 8484510 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (approximately 3 micrograms/mL) with 60% nitrous oxide
Number of subjects: 13
Study 8484510 — intervention group
Group type: COMPARATOR
Intervention: Esmolol infusion (100 micrograms.kg-1 x min-1) during propofol anesthesia
Number of subjects: 13
Study 3117150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer administration of 4 mg terbutaline
Number of subjects: 20
Study 3117150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler administration of 4 mg terbutaline
Number of subjects: 20
Study 3117150 — intervention group
Group type: COMPARATOR
Intervention: Control group (chronic hypoxia patients)
Number of subjects: 20